Fiche centre
Mayo Clinic in Florida
Jacksonville — United States
Essais liés10clinical trials
VilleJacksonvillelocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT05675410
Essais cliniques associés
10| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Acalabrutinib | Cancer | Phase 2 | NCT04115631 | A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma | ACTIVE_NOT_RECRUITING |
| Feasibility of Patient-Centered Home Care (PCHC) to Reduce Disparities in High-Risk Black Men (BM) With Prostate Cancer (CaP) | Cancer | À vérifier | NCT06470750 | Feasibility of Patient-Centered Home Care (PCHC) to Reduce Disparities in High-Risk Black Men (BM) With Prostate Cancer (CaP) | COMPLETED |
| Biopsy Procedure | Cancer | Phase 2/3 | NCT04628767 | Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer | RECRUITING |
| Biospecimen Collection | Cancer | Phase 3 | NCT06337318 | Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma | RECRUITING |
| VTx-002 | Sclérose latérale amyotrophique | Phase 1/2 | NCT07287397 | Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS | RECRUITING |
| PROMOTE — Gene Expression in Patients With Metastatic Prostate Cancer Receiving CYP-17 Inhibition Therapy | Cancer | À vérifier | NCT01953640 | PROMOTE — Gene Expression in Patients With Metastatic Prostate Cancer Receiving CYP-17 Inhibition Therapy | COMPLETED |
| Biospecimen Collection | Cancer | Phase 3 | NCT05675410 | A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab | RECRUITING |
| Donanemab | Alzheimer | Phase 2 | NCT07589595 | A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7) | RECRUITING |
| CC-97540 | Lupus | Phase 2 | NCT07015983 | A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE) | ACTIVE_NOT_RECRUITING |
| fMRI of Active DBS Stimulation in Epilepsy | Épilepsie | NA | NCT03870308 | fMRI of Active DBS Stimulation in Epilepsy | COMPLETED |